TITLE

Dia-B Tech: ISF402 progress promising but slow

PUB. DATE
March 2005
SOURCE
PharmaWatch: Monthly Review;Mar2005, Vol. 4 Issue 3, p23
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article presents a study conducted by Monash University, which identifies that the newly invented drug ISF402 could help type 2 diabetes sufferers lower blood glucose levels and enhance the effects of insulin in the U.S. The major advantage of the drug over existing therapies is that ISF is based on a naturally occurring peptide in human fluids with only four amino acids, so it is unlikely to have major side effects.
ACCESSION #
20950287

 

Related Articles

  • Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glulisine. Becker, Reinhard H. A.; Frick, Annke D. // Clinical Pharmacokinetics;2008, Vol. 47 Issue 1, p7 

    Insulin glulisine injection [3B-Lys, 29B-Glu-human insulin] is the newest human insulin analogue product for the control of mealtime blood sugar. As with insulin aspart and insulin lispro products, the insulin glulisine product displays faster absorption and onset of action, with a shorter...

  • Amino acids influence the glucose uptake through GLUT4 in CHO-K1 cells under high glucose conditions. Selvi, Radhakrishnan; Angayarkanni, Narayanasamy; Asma, Begum; Seethalakshmi, Thiagarajan; Vidhya, Srinivasan // Molecular & Cellular Biochemistry;Nov2010, Vol. 344 Issue 1/2, p43 

    ording to studies earlier, amino acids have proven to be antidiabetic, antiglycating, and anticataractogenic. The present study was to explore whether amino acids as mixtures could enhance glucose uptake in CHO-K1 cells specifically. The cells in F-12K1 serum-free medium were exposed to normal...

  • Your Insulin Therapy.  // American Family Physician;8/1/2004, Vol. 70 Issue 3, p511 

    Presents information on insulin therapy. Kinds of insulin; Symptoms of low blood sugar; Mealtime insulin type and dose.

  • Insulet: omnipresent treatment.  // PharmaWatch: Monthly Review;Mar2005, Vol. 4 Issue 3, p23 

    The article reports that Insulet Corp. has launch its first commercial product, the OmniPod Insulin Management System in the U.S. It has already received commercial clearance from the Food and Drug Administration. The two-part system will combine the healthcare benefits of continuous...

  • Cdk5-dependent regulation of glucose-stimulated insulin secretion. Fan-Yan Wei; Nagashima, Kazuaki; Ohshima, Toshio; Saheki, Yasunori; Yun-Fei Lu; Matsushita, Masayuki; Yamada, Yuichiro; Mikoshiba, Katsuhiko; Seino, Yutaka; Matsui, Hideki; Tomizawa, Kazuhito // Nature Medicine;Oct2005, Vol. 11 Issue 10, p1104 

    Tight glycemic control in individuals with diabetes mellitus is essential to prevent or delay its complications. Present treatments to reduce hyperglycemia mainly target the ATP-sensitive K+ (KATP) channel of pancreatic beta cells to increase insulin secretion. These current approaches are often...

  • Effect of buspirone on blood glucose levels in rats. Jadhav, Nisharani; Deshpande, Anita; Baradol, Ravikumar // National Journal of Physiology, Pharmacy & Pharmacology;2019, Vol. 9 Issue 10, p996 

    No abstract available.

  • Basalog® is similar to Lantus® in producing glycemic control in patients with type 1 diabetes mellitus on multiple daily insulin regimens. Verma, M.; Hazra, P.; Iyer, H.; Arun, A.; Akundi, S.; Dixit, M. N.; Eswaraiah, A.; Prasanna, C. G.; Atignal, A. // International Journal of Diabetes in Developing Countries;Feb2011, Vol. 31 Issue 1, p26 

    This study was performed to compare the insulin glargine produced by two different manufacturers. The study determines the efficacy and safety of a new insulin glargine (Basalog®) having the same amino-acid sequence as Lantus® in patients with type 1 diabetes mellitus on multiple daily...

  • ACUTE BRAIN INJURY DUE TO HYPOGLYCEMIA. Ohshiro, Yuzuru; Takasu, Nobuyuki // Current Medical Literature: Neurology;2005, Vol. 21 Issue 4, p65 

    The article presents information on a study which looks at how hypoglycemia can result in brain damage. Current theories are discussed which can explain how hypoglycemia causes a sudden, focal neural deficit. Reduced intracellular ATP and increased excitatory amino acids are two main events that...

  • 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and 1,2,3,4,7,8-Hexachlorodibenzo-p-Dioxin (HxCDD) Alter Body Weight by Decreasing Insulin-Like Growth Factor I (IGF-I) Signaling. Croutch, Claire R.; Lebofsky, Margitta; Schramm, Karl-Werner; Terranova, Paul F.; Rozman, Karl K. // Toxicological Sciences;May2005, Vol. 85 Issue 1, p560 

    2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) affects glycemia due to reduced gluconeogenesis; when combined with a reduction in feed intake, this culminates in decreased body weight. We investigated the effects of steady-state levels of TCDD (loading dose rates of 0.0125, 0.05, 0.2, 0.8, and 3.2...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics